JPWO2019044852A1 - レチノイドの副作用に対する感受性の決定方法 - Google Patents
レチノイドの副作用に対する感受性の決定方法 Download PDFInfo
- Publication number
- JPWO2019044852A1 JPWO2019044852A1 JP2019539546A JP2019539546A JPWO2019044852A1 JP WO2019044852 A1 JPWO2019044852 A1 JP WO2019044852A1 JP 2019539546 A JP2019539546 A JP 2019539546A JP 2019539546 A JP2019539546 A JP 2019539546A JP WO2019044852 A1 JPWO2019044852 A1 JP WO2019044852A1
- Authority
- JP
- Japan
- Prior art keywords
- snp
- susceptibility
- side effects
- retinoid
- retinoids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 title claims abstract description 85
- 150000004492 retinoid derivatives Chemical class 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 claims abstract description 56
- 239000002537 cosmetic Substances 0.000 claims abstract description 19
- 238000001514 detection method Methods 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims description 36
- 230000035945 sensitivity Effects 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 31
- 230000009471 action Effects 0.000 claims description 29
- 238000012545 processing Methods 0.000 claims description 24
- 238000003860 storage Methods 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 230000008859 change Effects 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 238000012216 screening Methods 0.000 claims description 12
- 239000000523 sample Substances 0.000 claims description 9
- -1 LOC643675 Proteins 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000012445 acidic reagent Substances 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 claims description 4
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 claims description 4
- 102100032537 Calpain-2 catalytic subunit Human genes 0.000 claims description 4
- 102100027867 FH2 domain-containing protein 1 Human genes 0.000 claims description 4
- 101000703754 Homo sapiens CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 claims description 4
- 101001049859 Homo sapiens Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 claims description 4
- 101000867692 Homo sapiens Calpain-2 catalytic subunit Proteins 0.000 claims description 4
- 101001060553 Homo sapiens FH2 domain-containing protein 1 Proteins 0.000 claims description 4
- 101000981680 Homo sapiens Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 Proteins 0.000 claims description 4
- 101000956606 Homo sapiens Ly6/PLAUR domain-containing protein 8 Proteins 0.000 claims description 4
- 101000577645 Homo sapiens Non-structural maintenance of chromosomes element 1 homolog Proteins 0.000 claims description 4
- 101000594780 Homo sapiens Olfactory receptor 14I1 Proteins 0.000 claims description 4
- 101000613810 Homo sapiens Osteocrin Proteins 0.000 claims description 4
- 101000800633 Homo sapiens Teneurin-2 Proteins 0.000 claims description 4
- 102100024102 Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 Human genes 0.000 claims description 4
- 102100038491 Ly6/PLAUR domain-containing protein 8 Human genes 0.000 claims description 4
- 102100028884 Non-structural maintenance of chromosomes element 1 homolog Human genes 0.000 claims description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 4
- 102100036095 Olfactory receptor 14I1 Human genes 0.000 claims description 4
- 102100040556 Osteocrin Human genes 0.000 claims description 4
- 102100033227 Teneurin-2 Human genes 0.000 claims description 4
- 108010040633 Transforming Protein 3 Src Homology 2 Domain-Containing Proteins 0.000 claims description 4
- 102000002013 Transforming Protein 3 Src Homology 2 Domain-Containing Human genes 0.000 claims description 4
- 238000009223 counseling Methods 0.000 claims description 4
- 239000002853 nucleic acid probe Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 238000004458 analytical method Methods 0.000 abstract description 7
- 230000002068 genetic effect Effects 0.000 abstract description 2
- 238000010187 selection method Methods 0.000 abstract 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 28
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 16
- 229960003471 retinol Drugs 0.000 description 12
- 235000020944 retinol Nutrition 0.000 description 12
- 239000011607 retinol Substances 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 11
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- 229960001727 tretinoin Drugs 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 229930002330 retinoic acid Natural products 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 101150086199 KCNMA1 gene Proteins 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000004299 exfoliation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108020003215 DNA Probes Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 2
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 241001262617 Japonica Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001821 nucleic acid purification Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
rs117761959、rs35515429、rs35736558、rs61840347、rs12754142、rs9290978、rs28501222、rs117675886、rs117758125、rs875705、rs58310152、rs58286474、rs112273273、rs73380909、rs73380910、rs73380913、rs12655922、rs17068781、rs278015、rs17068796、rs73381002、rs59490468、rs117142738、rs10086126、rs145653129、rs1903895、rs2574810、rs6480852、rs497578、rs562187、rs531402、rs2574801、rs2247887、rs2247880、rs814014、rs137908383、rs186198501、rs7933887、rs80067170、rs78606856、rs12100559、rs150171951、rs2060609、rs2060608、rs1349250、rs145745344、rs57595200、rs8008945、rs12907778、rs151092710、rs28363677、rs16948876、rs17753299、rs150302670、及びrs763038
からなる群から選ばれる、少なくとも1のSNPを検出する工程、
検出されたSNPに基づき、レチノイドの副作用に対する感受性を決定する工程
を含む、レチノイドの副作用に対する感受性の決定方法。
rs117761959、rs35515429、rs35736558、rs61840347、rs12754142、rs9290978、rs28501222、rs117675886、rs117758125、rs875705、rs58310152、rs58286474、rs112273273、rs73380909、rs73380910、rs73380913、rs12655922、rs17068781、rs278015、rs17068796、rs73381002、rs59490468、rs117142738、rs10086126、rs145653129、rs1903895、rs2574810、rs6480852、rs497578、rs562187、rs531402、rs2574801、rs2247887、rs2247880、rs814014、rs137908383、rs186198501、rs7933887、rs80067170、rs78606856、rs12100559、rs150171951、rs2060609、rs2060608、rs1349250、rs145745344、rs57595200、rs8008945、rs12907778、rs151092710、rs28363677、rs16948876、rs17753299、rs150302670、及びrs763038
からなる群から選ばれる少なくとも1のSNPに関する情報を記憶させた記憶部、
利用者のDNA情報を入力する入力部、
入力されたDNA情報中において、記憶されたSNPの存在を検出する処理部、
検出されたSNPに基づき、レチノイドの副作用に対する感受性を出力する出力部
を含む、コンピュータに関する。本発明のさらなる態様では、このようなコンピュータを制御する方法及び/又は制御プログラムにも関し、さらにかかる制御プログラムを格納した記憶媒体にも関する。このような記憶媒体は、不揮発性の媒体であることが好ましい。
候補薬剤を適用する工程、
適用された細胞において、下記の:CAPN2、OR14I1、LYPD8、OSTN、LOC643675、FHDC1、TENM2、LOC105375854、SHC3、KCNMA1、ST3GAL4、LINGO1、NSMCE1、及びLOC105372121からなる群から選ばれる少なくとも1の遺伝子の発現変化を決定する工程、また、遺伝子から翻訳された機能タンパク質の作用変化を評価する工程
前記発現変化、機能変化に基づき、候補薬剤のレチノイド感受性の制御を決定する、
候補薬剤のスクリーニング方法にも関する。
候補薬剤を含む溶液を適用する工程;
適用された細胞において遺伝子の発現変化を決定する工程;及び
前記発現変化に基づき、候補薬剤のレチノイド感受性に対する作用を決定する工程
を含む、候補薬剤のスクリーニング方法に関する。
候補薬剤を含む溶液を適用する工程;
適用された細胞において機能タンパクの作用への影響を評価する工程;及び
機能タンパク質の作用変化に基づき、候補薬剤のレチノイド感受性に対する作用を決定する工程
を含む、候補薬剤のスクリーニング方法に関する。
候補薬剤を含む溶液を適用する工程;
適用された細胞において遺伝子の発現を決定する工程;
適用された細胞において、機能タンパク質の作用への影響を評価する工程;及び
前記発現変化及び機能タンパク質の作用変化に基づき、候補薬剤のレチノイド感受性に対する作用を決定する工程
を含む、候補薬剤のスクリーニング方法に関する。
150名の被験者に対し、普段のスキンケアのお手入れに加えて、レチノール配合美容液を、2週間にわたって左右の目尻及び頬部を中心に全顔に1日2回(朝夜)塗布した。2週間の連用塗布後、外観写真を撮影し、問診を行うとともに、皮膚所見を判定した。
80名の被験者に対し、普段のスキンケアのお手入れに加えて、レチノール配合美容液を被験試料とし、被験試料からレチノールのみを抜去した製剤を対照試料として、ハーフフェイス法に基づいて試験を行った。具体的に、プラセボ対照ランダム化された被験試料と、対照試料とを、それぞれ左顔面及び右顔面に分けて9週間にわたり1日2回(朝夜)塗布した。試験開始前、及び9週間後に、外観写真を撮影し、問診を行うとともに、皮膚所見を判定した。
360名の被験者に対し、普段のスキンケアのお手入れに加えて、レチノール配合美容液を4週間にわたって左右の目尻及び頬部を中心に全顔に1日2回(朝夜)塗布した。4週間の連用塗布後、外観写真を撮影し、問診を行うとともに、皮膚所見を判定した。
試験1、試験2、及び試験3で得られた結果に基づき、レチノール感受性が反応群と健常群に分類した。具体的に、健常群は、レチノール試料の投与に対しトラブルが全く見られなかった被験者の群に関する。反応群は、副作用が明らかに認められ、レチノールに対する皮膚トラブルを経験した被験者の群に関する。
Claims (17)
- 以下の:
rs117761959、rs35515429、rs35736558、rs61840347、rs12754142、rs9290978、rs28501222、rs117675886、rs117758125、rs875705、rs58310152、rs58286474、rs112273273、rs73380909、rs73380910、rs73380913、rs12655922、rs17068781、rs278015、rs17068796、rs73381002、rs59490468、rs117142738、rs10086126、rs145653129、rs1903895、rs2574810、rs6480852、rs497578、rs562187、rs531402、rs2574801、rs2247887、rs2247880、rs814014、rs137908383、rs186198501、rs7933887、rs80067170、rs78606856、rs12100559、rs150171951、rs2060609、rs2060608、rs1349250、rs145745344、rs57595200、rs8008945、rs12907778、rs151092710、rs28363677、rs16948876、rs17753299、rs150302670、及びrs763038からなる群から選ばれる、少なくとも1のSNPを検出する工程、
検出されたSNPに基づき、レチノイドの副作用に対する感受性を決定する工程
を含む、レチノイドの副作用に対する感受性の決定方法。 - 前記SNPが以下の:rs1903895、rs2574810、rs6480852、rs497578、rs562187、rs531402、rs2574801、rs2247887、及びrs2247880からなる群から選ばれる、請求項1に記載の決定方法。
- 請求項1又は2に記載の方法により決定されたレチノイドの副作用に対する感受性に基づくカウンセリング方法。
- 請求項1又は2に記載の方法により決定されたレチノイドの副作用に対する感受性に基づいて化粧料を選択することを特徴とする、化粧料の提供方法。
- レチノイドの副作用に対する感受性を決定するコンピュータであって、以下の:
rs117761959、rs35515429、rs35736558、rs61840347、rs12754142、rs9290978、rs28501222、rs117675886、rs117758125、rs875705、rs58310152、rs58286474、rs112273273、rs73380909、rs73380910、rs73380913、rs12655922、rs17068781、rs278015、rs17068796、rs73381002、rs59490468、rs117142738、rs10086126、rs145653129、rs1903895、rs2574810、rs6480852、rs497578、rs562187、rs531402、rs2574801、rs2247887、rs2247880、rs814014、rs137908383、rs186198501、rs7933887、rs80067170、rs78606856、rs12100559、rs150171951、rs2060609、rs2060608、rs1349250、rs145745344、rs57595200、rs8008945、rs12907778、rs151092710、rs28363677、rs16948876、rs17753299、rs150302670、及びrs763038
からなる群から選ばれる少なくとも1のSNPに関する情報を記憶させた記憶部、
利用者のDNA情報を入力する入力部、
入力されたDNA情報中において、記憶されたSNPの存在を検出する処理部、
検出されたSNPに基づき、レチノイドの副作用に対する感受性を出力する出力部
を含む、コンピュータ。 - 前記コンピュータが、サーバーであり、入力部が通信部であり、出力部が通信部である、請求項5に記載のコンピュータ。
- 前記SNPが以下の:rs1903895、rs2574810、rs6480852、rs497578、rs562187、rs531402、rs2574801、rs2247887、及びrs2247880からなる群から選ばれる、請求項5又は6に記載のコンピュータ。
- 記憶部と、入力部と、処理部と、出力部とを含むレチノイドの副作用に対する感受性を決定するコンピュータを制御するプログラムであって、以下の:
rs117761959、rs35515429、rs35736558、rs61840347、rs12754142、rs9290978、rs28501222、rs117675886、rs117758125、rs875705、rs58310152、rs58286474、rs112273273、rs73380909、rs73380910、rs73380913、rs12655922、rs17068781、rs278015、rs17068796、rs73381002、rs59490468、rs117142738、rs10086126、rs145653129、rs1903895、rs2574810、rs6480852、rs497578、rs562187、rs531402、rs2574801、rs2247887、rs2247880、rs814014、rs137908383、rs186198501、rs7933887、rs80067170、rs78606856、rs12100559、rs150171951、rs2060609、rs2060608、rs1349250、rs145745344、rs57595200、rs8008945、rs12907778、rs151092710、rs28363677、rs16948876、rs17753299、rs150302670、及びrs763038からなる群から選ばれる少なくとも1のSNPに関する情報と、当該SNPと関連するレチノイドの副作用に対する感受性の情報とを記憶部に記憶させ、
入力部から、利用者のDNA情報を入力させ、
処理部に、入力されたDNA情報において記憶されたSNPの存在を検出させ、
処理部に、検出されたSNPに基づき、レチノイドの副作用に対する感受性を決定させ、
出力部に、レチノイドの副作用に対する感受性情報を出力させる、
前記プログラム。 - 前記コンピュータが、サーバーであり、入力部が通信部であり、出力部が通信部である、請求項8に記載のプログラム。
- 前記SNPが以下の:rs1903895、rs2574810、rs6480852、rs497578、rs562187、rs531402、rs2574801、rs2247887、及びrs2247880からなる群から選ばれる、請求項8又は9に記載のプログラム。
- 以下の:
rs117761959、rs35515429、rs35736558、rs61840347、rs12754142、rs9290978、rs28501222、rs117675886、rs117758125、rs875705、rs58310152、rs58286474、rs112273273、rs73380909、rs73380910、rs73380913、rs12655922、rs17068781、rs278015、rs17068796、rs73381002、rs59490468、rs117142738、rs10086126、rs145653129、rs1903895、rs2574810、rs6480852、rs497578、rs562187、rs531402、rs2574801、rs2247887、rs2247880、rs814014、rs137908383、rs186198501、rs7933887、rs80067170、rs78606856、rs12100559、rs150171951、rs2060609、rs2060608、rs1349250、rs145745344、rs57595200、rs8008945、rs12907778、rs151092710、rs28363677、rs16948876、rs17753299、rs150302670、及びrs763038
からなる群から選ばれる少なくとも1のSNPを検出するための核酸試薬を含む、レチノイドの副作用に対する感受性の決定のためのキット。 - 前記キットが、さらに核酸抽出及び精製試薬を含む、請求項11に記載のキット。
- 前記核酸試薬が、SNPを選択的に増幅可能なプライマーであり、前記キットがさらに、ポリメラーゼ、dNTPを含む、請求項11又は12に記載のキット。
- 前記核酸試薬が、核酸プローブであり、前記キットがさらに、プローブ検出試薬を含む、請求項11又は12に記載のキット。
- 前記SNPが以下の:rs1903895、rs2574810、rs6480852、rs497578、rs562187、rs531402、rs2574801、rs2247887、及びrs2247880からなる群から選ばれる、請求項11〜14のいずれか一項に記載のキット。
- 候補薬剤を適用する工程、
適用された細胞において、下記の:CAPN2、OR14I1、LYPD8、OSTN、LOC643675、FHDC1、TENM2、LOC105375854、SHC3、KCNMA1、ST3GAL4、LINGO1、NSMCE1、及びLOC105372121からなる群から選ばれる少なくとも1の遺伝子の発現変化を決定する工程、
前記発現の変化に基づき、候補薬剤のレチノイド感受性についての作用を決定する、
レチノイド感受性に対する作用について、候補薬剤をスクリーニングする方法。 - 候補薬剤を適用する工程、
適用された細胞において、下記の:CAPN2、OR14I1、LYPD8、OSTN、LOC643675、FHDC1、TENM2、LOC105375854、SHC3、KCNMA1、ST3GAL4、LINGO1、NSMCE1、及びLOC105372121からなる群から選ばれる少なくとも1の遺伝子から翻訳された機能タンパク質の作用変化を決定する工程、
前記機能タンパク質の作用変化に基づき、候補薬剤のレチノイド感受性についての作用を決定する、
レチノイド感受性に対する作用について、候補薬剤をスクリーニングする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017167230 | 2017-08-31 | ||
JP2017167230 | 2017-08-31 | ||
PCT/JP2018/031823 WO2019044852A1 (ja) | 2017-08-31 | 2018-08-28 | レチノイドの副作用に対する感受性の決定方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2019044852A1 true JPWO2019044852A1 (ja) | 2020-10-29 |
JP7267198B2 JP7267198B2 (ja) | 2023-05-01 |
Family
ID=65525627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019539546A Active JP7267198B2 (ja) | 2017-08-31 | 2018-08-28 | レチノイドの副作用に対する感受性の決定方法 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP7267198B2 (ja) |
TW (1) | TW201913431A (ja) |
WO (1) | WO2019044852A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7374634B2 (ja) * | 2019-07-12 | 2023-11-07 | 株式会社 資生堂 | レチノイドの副作用に対する感受性の決定方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035867A1 (fr) * | 1998-12-14 | 2000-06-22 | Nuclear Receptor Research Limited | Nouveaux ligands d'un recepteur nucleaire |
WO2009048123A1 (ja) * | 2007-10-11 | 2009-04-16 | Taiho Pharmaceutical Co., Ltd. | ビス(トリメチルシリル)フェニル化合物又はその塩、及びその用途 |
JP2016527307A (ja) * | 2013-08-08 | 2016-09-08 | ガルデルム セラピューティクス リミテッド | 胆汁酸−脂肪酸抱合体を含む抗座瘡組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8206920B2 (en) * | 2007-03-26 | 2012-06-26 | Arnold Ganser | Diagnostic assay for the specific treatment of acute myeloid leukemia |
JP2014524735A (ja) * | 2011-06-08 | 2014-09-25 | デノボ バイオファーマ (ハンジョウ) リミテッド カンパニー | レチノイドxレセプターの調節因子の活性を予測する方法および組成物 |
JP2013189397A (ja) * | 2012-03-14 | 2013-09-26 | Shiseido Co Ltd | 皮膚化粧料 |
-
2018
- 2018-08-28 WO PCT/JP2018/031823 patent/WO2019044852A1/ja active Application Filing
- 2018-08-28 JP JP2019539546A patent/JP7267198B2/ja active Active
- 2018-08-30 TW TW107130263A patent/TW201913431A/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000035867A1 (fr) * | 1998-12-14 | 2000-06-22 | Nuclear Receptor Research Limited | Nouveaux ligands d'un recepteur nucleaire |
WO2009048123A1 (ja) * | 2007-10-11 | 2009-04-16 | Taiho Pharmaceutical Co., Ltd. | ビス(トリメチルシリル)フェニル化合物又はその塩、及びその用途 |
JP2016527307A (ja) * | 2013-08-08 | 2016-09-08 | ガルデルム セラピューティクス リミテッド | 胆汁酸−脂肪酸抱合体を含む抗座瘡組成物 |
Non-Patent Citations (2)
Title |
---|
ALZOUBI, KAREM H. ET AL.: "The effect of genetic polymorphisms of RARA gene on the adverse effects profile of isotretinoin-trea", INT. J. CLIN. PHARMACOL. THER., vol. 51, JPN6018046172, 2013, pages 631 - 640, ISSN: 0004834153 * |
猪狩敦子 ほか: "遺伝子多型・総論(網羅的解析方法:SNP解析・DNAチップ・GWAS)", 血栓止血誌, vol. 23, JPN6022030689, 2012, pages 436 - 442, ISSN: 0004958860 * |
Also Published As
Publication number | Publication date |
---|---|
TW201913431A (zh) | 2019-04-01 |
WO2019044852A1 (ja) | 2019-03-07 |
JP7267198B2 (ja) | 2023-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7059332B2 (ja) | 肌特性解析方法 | |
Cadieux-Dion et al. | Expanding the clinical phenotype associated with ELOVL4 mutation: study of a large French-Canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratodermia | |
Ozaki et al. | A novel mutation in ELOVL4 leading to spinocerebellar ataxia (SCA) with the hot cross bun sign but lacking erythrokeratodermia: a broadened spectrum of SCA34 | |
Pham-Ledard et al. | High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type | |
Chapalain et al. | Is the loose anagen hair syndrome a keratin disorder?: A clinical and molecular study | |
Atzmony et al. | Second-hit, postzygotic PMVK and MVD mutations in linear porokeratosis | |
Daoud et al. | Resequencing of 29 candidate genes in patients with familial and sporadic amyotrophic lateral sclerosis | |
Marelli et al. | SCA15 due to large ITPR1 deletions in a cohort of 333 white families with dominant ataxia | |
Noreau et al. | SYNE1 mutations in autosomal recessive cerebellar ataxia | |
Mariani et al. | Expanding the spectrum of genes involved in Huntington disease using a combined clinical and genetic approach | |
Lücking et al. | Coding polymorphisms in the parkin gene and susceptibility to Parkinson disease | |
Levinsohn et al. | A somatic p. G45E GJB2 mutation causing porokeratotic eccrine ostial and dermal duct nevus | |
Bruttini et al. | Mutations in the myocilin gene in families with primary open-angle glaucoma and juvenile open-angle glaucoma | |
Jia et al. | Novel frizzled-4 gene mutations in chinese patients with familial exudative vitreoretinopathy | |
Aldahmesh et al. | Posterior microphthalmos as a genetically heterogeneous condition that can be allelic to nanophthalmos | |
Guettard et al. | Myoclonus-dystonia due to maternal uniparental disomy | |
Anheim et al. | Clinical and molecular findings of ataxia with oculomotor apraxia type 2 in 4 families | |
Sugiura et al. | Clouston syndrome with heterozygous GJB6 mutation p. Ala88Val and GJB2 variant p. Val27Ile revealing mild sensorineural hearing loss and photophobia | |
Fong et al. | Ichthyosis follicularis, atrichia, and photophobia syndrome associated with a new mutation in MBTPS2 | |
Wang et al. | A novel EDA1 missense mutation in X-linked hypohidrotic ectodermal dysplasia | |
JP7267198B2 (ja) | レチノイドの副作用に対する感受性の決定方法 | |
US20220051782A1 (en) | Methods and systems for informing product decisions | |
van Boheemen et al. | Cidofovir gel as treatment of follicular spicules in multiple myeloma | |
Lam et al. | Identification of variants in CNGA3 as cause for achromatopsia by exome sequencing of a single patient | |
De Jager et al. | An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210802 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220914 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230203 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20230203 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230209 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20230214 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230411 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230419 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7267198 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |